Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Intermedics PMA for cementless Natural Knee is approvable -- FDA panel.

This article was originally published in The Gray Sheet

Executive Summary

INTERMEDICS ORTHOPEDICS PMA FOR CEMENTLESS NATURAL KNEE needs additional benchtop fatigue testing data before it can be approved, FDA's Orthopedic and Rehabilitation Devices Panel concluded at a June 12 meeting in Gaithersburg, Maryland. The request for enhanced fatigue testing data, which the panel said should include additional comparisons to other prostheses, was one of several conditions placed on the advisory group's unanimous approvable recommendation for the premarket approval application. The panel's recommendation covered cementless implantation of the Natural Knee in patients suffering from either inflammatory joint disease or non-inflammatory degenerative joint disease.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT004268

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel